Maverex Market Access

Did you know that as well as Maverex being a full-service market access agency, we also support our clients with their environmental protection goals? Maverex supports global Pharma & MedTech companies to achieve market access and bring innovative interventions to patients worldwide. We are experts in demonstrating product value, from early clinical development to post-launch commercialisation. Our team is also uniquely positioned to support environmental goals, promoting sustainability in product development. Read about our capabilities below to learn more and contact [email protected] or message on LinkedIn to speak to one us. #heor #marketaccess #sustainability

Maverex is delighted to welcome Rebecca Brown to the team. Becky has recently joined the Value Communications team as a Principal Consultant. Becky brings over 8 years’ experience in Market Access, leading and developing HTA submissions for NICE, SMC, NCPE, DMC, NIPH and PBAC in multiple disease areas including oncology, cardiovascular disease, urology, and rare diseases. Becky also has extensive experience in the design and conduct of literature reviews to support HTA assessment and dissemination. We're thrilled to have her expertise and experience on our team! #newstarter #marketaccess #heor

At #ISPOREurope 2024, Maverex presented the findings of a study which quantified the potential greenhouse gas (GHG) emission savings from introducing faecal calprotectin (FCP) testing into the UK inflammatory bowel disease (IBD) diagnosis pathway. Through a reduction in unnecessary secondary care referrals and endoscopy investigations, FCP testing in the primary care setting could reduce GHG emissions by 495.66 tonnes CO2e annually. This GHG emission saving is equivalent to the average annual energy usage of 150 UK households. These findings highlight the importance of integrating sustainability into healthcare pathways to simultaneously improve patient outcomes and support global environmental goals. #sustainability #marketaccess #HEOR

The Maverex team had an amazing experience at #ISPOREurope 2024 last week. Our time in Barcelona was filled with engaging conversations, thought-provoking sessions, and opportunities to connect with professionals across the health economics and outcomes research community. Thank you to everyone who visited our stand and showed an interest in our services and research this year, particularly in Real-World Evidence, Health Economic Modelling, and our work in Environmental Impact Analysis. From exploring environmental sustainability strategies to shaping decision-making with cutting-edge health economic models, it’s clear that the market access challenges of today require robust, evidence-based solutions. If you didn’t get a chance to connect with us during the conference, contact us at [email protected] to learn how Maverex can support your Market Access and Research needs. #RealWorldEvidence #HEOR #EnvironmentalImpact

The Maverex team had a busy first day at #ISPOREurope yesterday and are looking forward to more interesting discussions throughout the remainder of the conference. Visit the team at booth 1213, or send us a message or email to [email protected] to arrange a meeting. #heor #marketaccess

The Maverex team have arrived in Barcelona and are ready for #ISPOREurope 2024! Stop by booth 1213 to speak to a member of the team or send us a message to organise an appointment. #HEOR #MarketAccess #EnvironmentalSustainability

The Maverex team has recently been involved in the development of a framework to estimate the environmental impact of a disease care pathway, using chronic kidney disease (CKD) as an example, published this week. The full paper can be found at the link below: https://lnkd.in/eY9g5s7m #environmentalimpact #lifecycleassessment

The environmental sustainability in healthcare team at Maverex will be presenting two posters at ISPOR Europe next week in Barcelona, showcasing how evaluating the environmental impact of care pathways can be used to inform decision-making. The first poster will be discussing how the introduction of faecal calprotectin testing into the UK inflammatory bowel disease diagnostic pathway reduced the environmental burden. For more information on this research, find us at poster session 1 from 10:30 on Monday 18th November (Poster code: HSD 16; main poster hall). The second poster will be discussing how adherence to NICE guidelines for COPD can improve patient outcomes as well as reducing the carbon footprint when compared with current clinical practice. For more information on this research, find us at poster session 5 from 9:00 on Wednesday 20th November (HSD 129; main poster hall). Throughout the conference you'll also be able to speak to members of the environmental sustainability in healthcare team at booth 1213 or you can contact [email protected] to set up an appointment.   #EnvironmentalSustainability #MarketAccess #HTA   

At #ISPOREurope 2024, Maverex will be presenting seven research posters, covering HTA insights, burden reviews and environmental assessments and sustainability in health care #HTA #Sustainability #MarketAccess

Maverex will be attending and presenting our research at ISPOR Europe in Barcelona, Spain from 17-20th November 2024. You can find us at booth #1213. Contact us on LinkedIn to arrange a meeting or send an email to [email protected] Sue Langham Antony Wright James Kenworthy Lizzie Adkins Nick Pooley Lindsay Nicholson Zoe Marjenberg Rhiannon Teague Gregor Skeldon